01—Abstract
Summary
Summary of the 8-K filed March 2, 2026. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation (Nasdaq: UTHR) furnished this Form 8-K under Item 7.01 (Regulation FD Disclosure) to report positive topline results from the phase 3 ADVANCE OUTCOMES study of ralinepag in patients with pulmonary arterial hypertension (PAH).
The study met its primary endpoint: ralinepag reduced the risk of a clinical worsening event by 55%a compared with placebo (hazard ratio 0.45, 95% CI 0.33-0.62; p<0.0001). The study enrolled 687 patients randomized 1:1, and 80% of patients were on dual background therapy at baseline. The company reported that ralinepag also produced statistically significant improvements versus placebo in several secondary endpoints, including six-minute walk distance, change in NT-proBNP, and clinical improvement, with the odds of clinical improvement increased by 47% from baseline to Week 28 (p=0.015).
The company stated that treatment was well-tolerated, with a safety profile consistent with known prostacyclin-related adverse events and no new safety signals. Headache, diarrhea, nausea, myalgia and jaw pain were the most commonly reported adverse events in the presentation, occurring more frequently with ralinepag than placebo. United Therapeutics intends to present full results at an upcoming international conference and to submit a New Drug Application for ralinepag to the FDA by the second half of 2026.
The company hosted a webcast at 8:30 a.m. Eastern Time on March 2, 2026, and the investor slides (Exhibit 99.2) were also posted to its website.
02—Key points
Key Highlights
- Primary endpoint met: ralinepag reduced the risk of clinical worsening by 55% vs. placebo (HR 0.45, 95% CI 0.33-0.62; p<0.0001) in the phase 3 ADVANCE OUTCOMES study.
- Clinical worsening events occurred in 64 ralinepag patients (18.3%) versus 121 placebo patients (35.9%), with disease progression events at 2.9% vs. 10.7%.
- Key secondary endpoints met, including six-minute walk distance, change in NT-proBNP, and clinical improvement; odds of clinical improvement increased by 47% (p=0.015).
- Study enrolled 687 patients with PAH (350 ralinepag, 337 placebo); 80% were on dual background therapy and 70% were WHO/NYHA Functional Class II at baseline.
- Safety: described as well-tolerated and consistent with known prostacyclin-related adverse events, with no new safety signals; headache (81.1% vs. 41.5%) was the most common adverse event.
- Regulatory plan: company intends to submit an NDA for ralinepag to the FDA by the second half of 2026 and present full results at an upcoming international conference.
- Ralinepag is described as a once-daily oral prostacyclin receptor agonist, positioned as the first and only once-daily oral prostacyclin by the company.
03—Questions
Frequently Asked Questions
What did the ADVANCE OUTCOMES study find?
The phase 3 study met its primary endpoint. Ralinepag reduced the risk of a time-to-first adjudicated clinical worsening event by 55% compared with placebo (hazard ratio 0.45, 95% CI 0.33-0.62; p<0.0001) in patients with PAH.
What is the regulatory timeline for ralinepag?
United Therapeutics intends to submit a New Drug Application for ralinepag to the U.S. Food and Drug Administration by the second half of 2026. The filing states that the use of ralinepag for PAH is investigational and has not been approved by the FDA.
How was the study designed?
ADVANCE OUTCOMES was a pivotal, global, randomized, double-blind, placebo-controlled, event-driven study of 687 patients with PAH, randomized 1:1 to ralinepag or placebo on top of standard PAH background therapy. The primary endpoint was time to first adjudicated clinical worsening event.
Were there any safety concerns reported?
The company stated that treatment was well-tolerated, with a safety profile consistent with known prostacyclin-related adverse events and no new safety signals. The presentation showed higher rates of headache, diarrhea, nausea, myalgia and jaw pain with ralinepag than with placebo.
Where can investors access the results and materials?
The company hosted a webcast at 8:30 a.m. Eastern Time on March 2, 2026, with a rebroadcast available for one year. The investor presentation slides were furnished as Exhibit 99.2 and were also to be posted to the company's website.
04—Continue